α-Ethyl-1-naphthalinmethanamin | 22038-83-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: α-Ethyl-1-naphthalinmethanamin
• 英文别名: 1-[1]naphthyl-propylamine；1-(Naphthalen-1-yl)propan-1-amine；1-naphthalen-1-ylpropan-1-amine
• CAS: 22038-83-1
• 化学式: C₁₃H₁₅N
• 分子量: 185.269
• InChiKey: JJYPGFPZTOUPHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  α-Ethyl-1-naphthalinmethanamin 在 sodium tetrahydroborate 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 27.0h， 生成 N-<4-(1,1-Dimethylethyl)phenylmethyl>-α-ethyl-N-methyl-1-naphthalinmethanamin-Hydrochlorid
  参考文献：
  名称：

  合成具有布替萘芬结构元件构象固定的潜在角鲨烯环氧化酶抑制剂

  摘要：

  报道了萘甲胺 6b-h 的合成，其中将空间要求增加的取代基引入 α 位置以进行构象固定。由于萘基烷酮 3 与胺 9 和 10 的还原胺化现在可以在非常有限的范围内使用，因此首先以各种方式合成 α-取代萘甲胺 2 和 4 作为合适的中间体，然后才合成所需的 N 取代模式目标化合物通过合适的 - 主要是还原 - 烷基化方法建立。

  DOI：

  10.1002/ardp.19933260607
• 作为产物：
  描述：

  1-(1-naphthyl)-1-propanol 以58%的产率得到
  参考文献：
  名称：

  Stanetty Peter, Wallner Herbert, Arch. Pharm., 326 (1993) N 6, S 341- 350

  摘要：

  DOI：

文献信息

• NITROGENOUS COMPOUNDS AND ANTIVIRAL DRUGS CONTAINING THE SAME
  申请人：Kureha Chemical Industry Co., Ltd.

  公开号：EP1273571A1

  公开（公告）日：2003-01-08

  The present invention provides novel compounds having antiviral activities and antiviral drugs containing the compounds as the active ingredient. The compounds are shown by the following general formula (1), wherein typically A1 and A2 are each guanidine or a group of the general fomula (ia) ; A3 is a mono- or poly-cyclic heteroaromatic ring contining 1 or 2 heteroatoms ; B1 is a single bond or alkylene group; R1 is hydrogen or alkyl group; W is an alkylene having 2-3 carbons, a cycloalkylene having 5-10 carbons, aromatic ring having 6-10 carbons, or a heteroaromatic ring having 5-10 carbons; y is C(=O)-; x is -C(=O)-NH-; n1 is an integer of 1-2; n2 is an integer of 2-3; D is a substituent selected from among various groups.

  本发明提供了具有抗病毒活性的新化合物以及含有这些化合物作为活性成分的抗病毒药物。这些化合物由以下一般式（1）所示，其中通常A1和A2分别是胍或一般式（ia）的基团；A3是含有1个或2个杂原子的单环或多环杂芳环；B1是单键或烷基基团；R1是氢或烷基基团；W是具有2-3个碳的烷基、具有5-10个碳的环烷基、具有6-10个碳的芳香环或具有5-10个碳的杂芳环；y是C(=O)-；x是-C(=O)-NH-；n1是1-2的整数；n2是2-3的整数；D是从各种基团中选择的取代基。
• CXCR4-ANTAGONISTIC DRUGS COMPRISING NITROGEN-CONTAINING COMPOUND
  申请人：Kureha Chemical Industry Co., Ltd.

  公开号：EP1389460A1

  公开（公告）日：2004-02-18

  To provide novel nitrogen-containing compounds having antagonism to CXCR4 and remedies for disease, such as rheumatism, cancer metastasis, etc., based on the CXCR4 antagonism. Nitrogen-containing compounds represented by the following general formula and CXCR4 antagonists containing these compounds as an active ingredient can be provided. The above compounds are typified by nitrogen-containing compounds represented by the following general formula (I) wherein A1 and A2 represent each a guanidino group or a group represented by the following general formula (ia) (wherein A3 represents a monocyclic or polycyclic heterocyclic aromatic ring group having 1 or 2 hetero atoms; B1 represents a single bond or alkylene group; and R1 represents hydrogen or alkyl group; W represents alkylene group having 2 to 3 carbon atoms, cyclic alkylene group having 5 to 10 carbon atoms, aromatic ring having 6 to 10 carbon atoms or heterocyclic aromatic ring having 5 to 10 carbon atoms; y is - (C=O) -; x is -C (=O) -NH-; n1 is an integer of 1 or 2; n2 is an integer of 2 or 3; and D is selected from among various substituents:

  为基于CXCR4拮抗作用提供对CXCR4具有拮抗作用的新型含氮化合物和治疗风湿病、癌症转移等疾病的药物。以下是一般式代表的含氮化合物和以这些化合物为活性成分的CXCR4拮抗剂。上述化合物以以下一般式（I）代表的含氮化合物为代表，其中A1和A2分别代表鸟氨基基团或由以下一般式（ia）代表的基团（其中A3代表具有1个或2个杂原子的单环或多环杂环芳香环基团；B1代表单键或烷基基团；R1代表氢或烷基基团；W代表具有2至3个碳原子的烷基基团、具有5至10个碳原子的环烷基团、具有6至10个碳原子的芳香环或具有5至10个碳原子的杂环芳香环；y为-(C=O)-；x为-C(=O)-NH-；n1为1或2的整数；n2为2或3的整数；D从各种取代基中选择）。
• [EN] SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF<br/>[FR] DÉRIVÉS DE SULFONAMIDE ET LEURS APPLICATIONS PHARMACEUTIQUES
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2015158313A1

  公开（公告）日：2015-10-22

  Provided herein are sulfonamide derivatives or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and their uses for treating Alzheimer's disease. Also provided herein are pharmaceutical compositions containing such compounds, and use of such compounds or pharmaceutical compositions thereof for managing or treating 5-HT6 receptor-mediated diseases, especially in the manufacture of a medicament for managing or treating Alzheimer's disease.

  本文提供了磺胺衍生物或其立体异构体、几何异构体、互变异构体、N-氧化物、水合物、溶剂合物、代谢物、药用可接受的盐或其前药，以及它们用于治疗阿尔茨海默病的用途。本文还提供了含有这些化合物的药物组合物，并使用这些化合物或其药物组合物来管理或治疗5-HT6受体介导的疾病，特别是用于制造治疗或管理阿尔茨海默病的药物。
• Nitrogenous compounds and antiviral drugs containing the same
  申请人：——

  公开号：US20040092556A1

  公开（公告）日：2004-05-13

  The present invention provides novel compounds having antiviral activities and antiviral drugs containing the compounds as the active ingredient. The compounds are shown by the following general formula (1), wherein typically A 1 and A 2 are each guanidine or a group of the general fomula (ia); A 3 is a mono- or poly-cyclic heteroaromatic ring contining 1 or 2 heteroatoms; B 1 is a single bond or alkylene group; R 1 is hydrogen or alkyl group; W is an alkylene having 2-3 carbons, a cycloalkylene having 5-10 carbons, aromatic ring having 6-10 carbons, or a heteroaromatic ring having 5-10 carbons; y is C(═O)—; x is —C(═O)—NH—; n 1 is an integer of 1-2; n 2 is an integer of 2-3; D is a substituent selected from among various groups. 1

  本发明提供了具有抗病毒活性的新化合物和包含该化合物作为活性成分的抗病毒药物。该化合物由以下通式（1）表示，其中通常A1和A2分别是鸟氨酸或通式（ia）的基团；A3是含有1或2个杂原子的单环或多环杂芳基环；B1是单键或烷基链；R1是氢或烷基基团；W是具有2-3个碳的烷基，具有5-10个碳的环烷基，具有6-10个碳的芳环基或具有5-10个碳的杂芳基环；y是C（═O）-；x是-C（═O）-NH-；n1是1-2的整数；n2是2-3的整数；D是从各种基团中选择的取代基。
• Cxcr4-antagonistic drugs composed of nitrogen-containing compound
  申请人：——

  公开号：US20040157818A1

  公开（公告）日：2004-08-12

  To provide novel nitrogen-containing compounds having antagonism to CXCR4 and remedies for disease, such as rheumatism, cancer metastasis, etc., based on the CXCR4 antagonism. Nitrogen-containing compounds represented by the following general formula and CXCR4 antagonists containing these compounds as an active ingredient can be provided. The above compounds are typified by nitrogen-containing compounds represented by the following general formula (I) 1 wherein A 1 and A 2 represent each a guanidino group or a group represented by the following general formula (ia) 2 (wherein A 3 represents a monocyclic or polycyclic heterocyclic aromatic ring group having 1 or 2 hetero atoms; B 1 represents a single bond or alkylene group; and R 1 represents hydrogen or alkyl group; W represents alkylene group having 2 to 3 carbon atoms, cyclic alkylene group having 5 to 10 carbon atoms, aromatic ring having 6 to 10 carbon atoms or heterocyclic aromatic ring having 5 to 10 carbon atoms; y is —(C═O)—; x is —C (═O)—NH—; n 1 is an integer of 1 or 2; n 2 is an integer of 2 or 3; and D is selected from among various substituents:

  为了基于CXCR4拮抗作用提供具有对CXCR4拮抗作用的新型含氮化合物和治疗药物，例如风湿病、癌症转移等。可以提供以下通式所表示的含氮化合物和包含这些化合物作为活性成分的CXCR4拮抗剂。上述化合物的典型代表是由以下通式（I）所表示的含氮化合物： 其中，A1和A2分别表示鸟氨酸基团或由以下通式（ia）所表示的基团： （其中，A3表示具有1或2个杂原子的单环或多环杂环芳香基团；B1表示单键或烷基链；R1表示氢或烷基链；W表示具有2至3个碳原子的烷基链、具有5至10个碳原子的环状烷基链、具有6至10个碳原子的芳香环或具有5至10个碳原子的杂环芳香环；y为—（C═O）—；x为—C(═O)—NH—；n1为1或2的整数；n2为2或3的整数；D从各种取代基中选择。